Intravenous landiolol for the prevention of atrial fibrillation after aortic root, ascending aorta, and aortic arch surgery: A propensity score-matched analysis

Jun Kaminohara, MD,a Masahiko Hara, MD, PhD,b,c Kenji Uehara, MD, PhD,a,d Maya Suruga, MD,a,e Keiji Yunoki, MD, PhD,f and Makoto Takatori, MD, PhDabg

ABSTRACT

Objective: Postoperative atrial fibrillation (POAF) after cardiac surgery is associated with increased mortality. The efficacy of landiolol hydrochloride for POAF prevention after coronary artery bypass grafting procedure and valve surgery has been reported. However, little evidence is available on its role in POAF prevention after aortic root, ascending aorta, and aortic arch surgery. This study aimed to determine the association between intravenous landiolol and the incidence of POAF after these aortic surgeries.

Methods: We included 358 consecutive adult patients without preoperative atrial fibrillation who underwent aortic root, ascending aorta, and aortic arch surgery between January 1, 2011, and December 31, 2018, at our institution. The therapeutic influence of landiolol in preventing POAF was estimated by propensity score-matched analysis (n = 222). The primary end point was the incidence of POAF within 72 hours after surgery. The secondary end points included adverse clinical events such as 30-day mortality and symptomatic cerebral infarction.

Results: The median age of the cohort was 72 years, 68.5% were men, and 46.4% received postoperative oral or transdermal β-blockers. After minimizing differences in patient background by propensity score matching, the incidence of POAF in the landiolol group was significantly lower than that in the reference group (18.9% vs 38.7%; P = .002). Landiolol use was associated with reduced incidence of POAF (odds ratio, 0.39; 95% CI, 0.21 to 0.72; P = .003). There were no significant differences in secondary end points.

Conclusions: Intravenous landiolol was associated with a lower incidence of POAF after aortic root, ascending aorta, and aortic arch surgery. (JTCVS Open 2022;11:49-58)

CENTRAL MESSAGE

In a propensity score-matched cohort, intravenous landiolol was related with a lower incidence of postoperative atrial fibrillation after aortic root surgery.

PERSPECTIVE STATEMENT

Several trials have shown that intravenous landiolol prevents POAF after cardiac surgeries, but its role after aortic root, ascending aorta, and aortic arch surgery is unclear. We found that landiolol is associated with lower POAF incidence. Physicians or surgeons should consider landiolol as a therapeutic option for POAF prevention after these surgeries.

Video clip is available online.
with a preoperative history of any type of AF were excluded from the study population. Perioperative data shown in Tables 1 through 4 and Figure 1 were retrospectively collected from surgical or patient clinical records. The study protocol complied with the standards outlined in the Declaration of Helsinki and was approved by the Ethics Committee of Hiroshima Citizens Hospital (approval No.: 30-117; December 14, 2018). The requirement for informed consent was waived due to the retrospective nature of the present study. The opt-out option granted patients the right to be excluded from the study.

### Perioperative Management

Regarding preoperative beta-blocker use, this was continued until the day of surgery for regular users, and no new doses were started for non-users. Aortic surgery was performed under general anesthesia with intubation. Anesthesia was induced and maintained using intravenous propofol in combination with the inhalation of sevoflurane for sedation. Fentanyl or remifentanil for analgesia, and rocuronium for muscle relaxation. For root or ascending aortic replacement, after median sternotomy and systemic heparization (300 U/kg), the ascending aorta was cannulated for systemic perfusion, whereas the right atrium, or the superior and inferior venae cavae were cannulated for venous drainage to establish cardiopulmonary bypass (CPB). Following crossclamping at the ascending aorta, cardiac arrest was obtained by antegrade infusion of cardioplegic solution using St Thomas solution No. 2 (Miotector; Fuso Pharmaceutical Industries, Ltd) into the coronary circulation at 15 mL/kg, with additional infusion of 7.5 mL/kg every 30 minutes thereafter for maintaining the status. Retrograde infusion of the cardioplegic solution was combined when concomitant coronary dissection or moderate to severe aortic regurgitation was present. Aortic graft replacement was performed under cardiac arrest and CPB support. The body temperature during CPB was set around 32 to 34 °C.

Regarding aortic arch replacement, we used the antegrade selective cerebral perfusion method for all patients. Details of the procedure have previously been reported from our institution and can be summarized as follows. The brachiocephalic artery and the femoral artery were used for systemic perfusion, and the right atrium or the superior and inferior venae cavae were cannulated for venous drainage to establish CPB. Body temperature control was started at the initiation of CPB, and the target temperature was set at 28 °C, which was achieved within 30 minutes from CPB initiation. In cases where anatomical anatomy of the aorta was difficult because of anatomical malformation or severe aortic diseases, a lower body temperature (moderate hypothermia was defined as body temperature >20 to ≤28 °C) was considered to maintain brain and renal function. After crossclamping and antegrade crystalloid cardioplegia infusion as stated above, the artificial graft was anastomosed to the proximal aortic stump. After cooling to the target temperature and performing a proximal graft anastomosis, systemic circulation was arrested and the diseased aorta was resected. Subsequently, antegrade selective cerebral perfusion was instituted. During open distal anastomosis, blood perfusion to the lower body was paused. After completion of the distal anastomosis, lower body circulation was restarted and the body temperature was restored to normal during the left subclavian, left cervical, and innominate arteries reconstructions. After the aortic surgery, all patients were transferred to the ICU.

During the study period, landiolol was administered to prevent new-onset AF in approximately 4 out of 7 patients, and the decision of administration was based on the discretion of the attending anesthesiologist and/or cardiac surgeon (Figure 1). Intravenous landiolol was started at the time of withdrawal from CPB in the operating theater or within 3 hours after admission to the ICU. More specifically, it was started using a syringe pump when weaning from the CPB if the mean blood pressure was maintained above 70 mm Hg. If there were signs of conduction abnormality, administration was not performed. In contrast, if the heart rate was simply low and <60 bpm with hemodynamic stability, administration was started with backup pacing. When blood pressure could not be maintained above

---

**Abbreviations and Acronyms**

- **AF** = atrial fibrillation
- **CPB** = cardiopulmonary bypass
- **ICU** = intensive care unit
- **IPTW** = inverse probability of treatment weighting
- **POAF** = postoperative atrial fibrillation
- **PS** = propensity score
- **RASI** = renin-angiotensin system inhibitor

---

**METHODS**

**Study Patients**

Among the 462 adult patients (aged ≥18 years) who underwent aortic root, ascending aorta, and aortic arch surgery at Hiroshima Citizens Hospital between January 1, 2011, and December 31, 2018, 358 patients without preoperative AF were retrospectively included in the present study (Figure 1). We included patients with or without CABG or any kind of valve surgery. To meet the eligibility criteria shown in Figure 1, 46 patients...
70 mm Hg after weaning from CPB, landiolol administration was continued in combination with fluid loading and/or inotropic agents. Landiolol was initiated or titrated at an infusion rate of 0.25 to 5.0 μg/kg/min. Landiolol infusion was discontinued if prolonged hemodynamic instability (bradycardia or hypotension) ensued or whenever an oral or transdermal beta-blocker was administered. The initiation of postoperative oral or transdermal beta-blockers was also at the discretion of the attending anesthesiologist and/or cardiac surgeon. However, there was a conflict that oral or transdermal beta-blocker use for the prevention of POAF was not covered by medical insurance in Japan during the study period. Patients usually received 2.5 to 5.0 mg carvedilol or 1.25 to 2.5 mg bisoprolol after extubation. If patients were not able to take the medication orally, a transdermal 4.0-mg bisoprolol patch was considered.

End Points

The primary end point was set as the incidence of new-onset POAF. We defined AF as an irregular narrow complex rhythm with absent P waves lasting more than 1 minute on continuous electrocardiogram monitoring. New-onset AF was defined as AF that occurred within 72 hours postoperatively, based on previous reports that the peak incidence of new-onset AF falls between 48 and 72 hours.18,26,27 Patients were continuously monitored in the ICU and wards using 3-lead electrocardiograms until hospital discharge.

Secondary end points included 30-day mortality, 30-day symptomatic cerebral infarction, 30-day readmission for arrhythmia after discharge, AF at discharge, length of hospital stay, length of ICU stay, length of mechanical ventilation, need for pacemaker support (using pacemaker for stability of hemodynamics), and mean blood pressure and heart rate during the first 72 hours of ICU admission. The mean blood pressure and heart rate were determined by extracting each of the 72-hour postoperative measurements maintained in the electronic medical record of the postoperative ICU.

Statistical Analysis and PS Matching

Continuous variables are summarized using the median with first and third quartiles, and categorical variables using frequency with percentages. The study population was first divided into two groups according to landiolol use (landiolol vs reference groups). To estimate the influence of landiolol on the incidence of POAF, logistic regression analyses with 95% CI were performed on a PS-matched population by parity. IPTW was used to evaluate the robustness of the result. PS-matching was performed using the caliper matching method, as previously reported, with a caliper width of 0.2 SD.28 Explanatory variables for calculating PS and weights of IPTW were selected clinically based on previous reports and included the following: age, sex, body mass index, past medical history (ie, hypertension, dyslipidemia, diabetes mellitus, and smoking), preoperative medication (ie, renin-

FIGURE 1. Eligibility criteria and selection flow diagram of the study population. ICU, Intensive care unit.
The image contains a table titled "TABLE 1. Baseline characteristics of the total study population and propensity score-matched cohort." The table compares the characteristics of a total study population and a matched cohort across different categories. The data include baseline characteristics such as operation type, past history, preoperative medication, laboratory data, echocardiography, intraoperative factors, and postoperative medication. The text also mentions the use of angiotensin system inhibitor (RASI), beta-blocker, and statin, postoperative use of oral or transdermal beta-blocker within 72 hours after surgery, laboratory data (including preoperative estimated glomerular filtration rate, preoperative echocardiography, and peri-operative indices), and the minimum value within 72 hours after operation.

Continuous variables are presented as median (first quartile-third quartile) and categorical variables are presented as n (percentage). SMD, Standardized mean difference; CABG, coronary artery bypass grafting; RASI, renin-angiotensin system inhibitor; e-GFR, estimated glomerular filtration rate; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass. *The dose of beta-blocker is presented in terms of carvedilol. For oral drugs, the carvedilol dose was 4 times the bisoprolol dose, and for transdermal drugs, the carvedilol dose was 2.5 times the bisoprolol dose. Inotropic agents included dopamine, dobutamine, noradrenaline, milrinone, and adrenaline. Moderate hypothermia was defined as a body temperature >20 to ≤28°C. | The minimum value within 72 hours after operation. |
TABLE 2. Timing, administration dose, and the total amount of prophylactic landiolol used

| Variable                        | Total study population (n = 201) | Matched cohort (n = 111) |
|---------------------------------|-----------------------------------|--------------------------|
|                                | Landiolol initiation at           |                          |
| Operation room                  | 192 (95.5)                        | 106 (95.5)               |
| Within 3 h after ICU admission  | 9 (4.5)                           | 5 (4.5)                  |
|                                | Landiolol dose rate at            |                          |
| Operation room                  | 1.0 (0.5-1.0)                     | 1.0 (0.5-1.0)            |
| (µg/kg/min)                     | ICU (µg/kg/min)                   | 1.0 (1.0-1.0)            |
| Total dose (mg)                 | 169.6 (94.3-266.1)               | 169.6 (90.5-263.7)       |
| Total duration (h)              | 48.3 (34.6-71.3)                  | 51 (30.3-73.5)           |

Continuous variables are presented as median (first quartile-third quartile) and categorical variables are presented as n (%). ICU, Intensive care unit.

RESULTS

Figure 1 shows the eligibility criteria of the total study population. We included 358 eligible patients, of whom 201 received prophylactic landiolol for the prevention of POAF and 157 patients who did not. There were no patients with advanced atrioventricular block or sick sinus syndrome. Finally, 222 patients were matched, with 111 patients in each group (Figure 1). Table 1 shows the characteristics of the total study population and of the PS-matched cohort.

Differences in background characteristics were minimized and almost well-balanced after PS-matching with considering parity in the PS-matched cohort were employed to evaluate differences in categorical variables, with Fisher exact test used when the expected values in any of the cells of a contingency table were below 5. Ad-hoc subgroup analysis was also performed among 4 different treatment groups: landiolol plus postoperative oral or transdermal beta-blocker, landiolol alone, postoperative oral or transdermal beta-blocker alone, and neither of these agents. The differential effects of landiolol and oral/transdermal beta-blockers were tested with the interaction P value, and multiple pairwise comparisons performed. The pairwise comparisons were not adjusted for multiplicity. There were no missing data in the study population, including the PS-matched cohort. All analyses were performed using Microsoft R Open, version 3.5.1 (Microsoft Corporation).

TABLE 3. Incidence of primary and secondary end points in the total study population and propensity score-matched cohort

| Primary end point | Parameter | Total study population (n = 358) | Landiolol (n = 201) | Reference (n = 157) | P value |
|-------------------|-----------|---------------------------------|---------------------|---------------------|---------|
| POAF              | Burden    | 95 (26.5)                       | 36 (17.9)           | 59 (37.6)           | <.001   |
|                   | Duration (min) | 377 (177-971)   | 467 (208-1238)      | 285 (128-758)       | .199    |
|                   | Electrical cardioversion | 63 (66.3)     | 27 (75.0)           | 36 (61.0)           | .162    |
|                   | Pharmacological cardioversion | 43 (45.3)   | 20 (55.6)           | 23 (39.0)           | .115    |
|                   | 30-d mortality | 4 (1.1)     | 0 (0.0)             | 4 (2.5)             | .023    |
|                   | 30-d symptomatic cerebral infarction | 27 (7.5) | 10 (5.0)           | 17 (10.8)           | .037    |
|                   | 30-d hospital readmission for arrhythmia after discharge | 1 (2.2) | 1 (2.5)          | 0 (0.0)            | .999    |
|                   | AF at discharge | 8 (2.2)    | 1 (0.5)             | 7 (4.5)             | .024    |
|                   | Length of hospital stay (d) | 31 (25-41)  | 30 (26-39)          | 32 (24-43)          | .910    |
|                   | Length of ICU stay (d) | 5 (3-7)    | 4 (3-6)             | 5 (4-7)             | .013    |
|                   | Length of mechanical ventilation (h) | 14.7 (8.5-23.2) | 14.7 (8.1-23.6) | 14.6 (9.6-21.5) | .517    |
|                   | Needs for PM support | 148 (41.3) | 68 (33.8)          | 80 (51.0)           | .001    |
|                   | Mean BP over 72 h (mm Hg) | 78 (74-82) | 78 (74-82)        | 79 (74-83)          | .159    |
|                   | Mean HR over 72 h (bpm) | 80 (74-84) | 80 (74-84)       | 79 (75-84)          | .755    |

Secondary end points

| Parameter                                      | Total (n = 222) | Landiolol (n = 111) | Reference (n = 111) | P value |
|-----------------------------------------------|-----------------|---------------------|---------------------|---------|
| 30-d mortality                                | 4 (1.4)         | 0 (0.0)             | 3 (2.7)             | .247    |
| 30-d symptomatic cerebral infarction          | 27 (9.0)        | 9 (8.1)             | 11 (9.9)            | .655    |
| 30-d hospital readmission for arrhythmia after discharge | 1 (2.2) | 0 (0.0)          | 0 (0.0)             | -       |
| AF at discharge                               | 8 (2.7)         | 1 (0.9)             | 5 (4.5)             | .212    |
| Length of hospital stay (d)                   | 31 (26-43)      | 31 (26-43)          | 32 (24-43)          | .620    |
| Length of ICU stay (d)                        | 5 (4-7)         | 5 (4-7)             | 5 (4-7)             | .646    |
| Length of mechanical ventilation (h)          | 14.7 (10.3-25.8) | 15.6 (10.0-30.0)  | 14.9 (11.3-21.3)    | .943    |
| Needs for PM support                          | 148 (41.3)      | 68 (33.8)           | 80 (51.0)           | .001    |
| Mean BP over 72 h (mm Hg)                     | 78 (74-83)      | 78 (74-83)          | 79 (74-83)          | .449    |
| Mean HR over 72 h (bpm)                       | 80 (74-83)      | 80 (74-83)          | 79 (74-83)          | .797    |

Continuous variables are presented as median (first quartile-third quartile) and categorical variables are presented as n (%). POAF: Postoperative atrial fibrillation; AF: Atrial fibrillation; ICU: Intensive care unit; PM: Pacemaker; BP: Blood pressure; HR: Heart rate. *Fisher exact test.
an SMD <0.1 (Table 1 and Figure 2). The distributions of PS were also well balanced with a median PS of 0.54 (interquartile range, 0.39-0.64) in the landiolol group versus 0.53 (0.39-0.64) in the reference group (Figure 2). Nevertheless, there were slight differences in sex, prevalence of hypertension, diabetes mellitus, statin use, and duration of CPB time (Table 1). In the PS-matched cohort, the median age was 72 years (interquartile range [IQR], 65-77 years). Moreover, 152 (68.5%) patients were men, 175 (78.8%) had hypertension, 116 (52.3%) took RASI preoperatively, 73 (32.9%) took preoperative beta-blockers, and 103 (46.4%) received postoperative oral or transdermal beta-blockers. The median preoperative left ventricular ejection fraction was 67% (interquartile range, 63%-71%), and 43 (19.4%) patients underwent emergency surgery. Regarding hypothermia, 170 (76.6%) patients experienced moderate hypothermia (defined as a body temperature >20 to ≤28°C) for median of 48 minutes (IQR, 3-68 minutes).

Table 2 shows the timing, administration dose, and the total amount of prophylactic landiolol administration. Landiolol was started at the operation room in 106 (95.5%) patients, whereas the remaining 5 (4.5%) patients received landiolol within 3 hours after ICU admission. The median dose rate was 1.0 μg/kg/min and the total amount of prophylactic landiolol administered was 169.6 mg (IQR, 90.5-263.7 mg).

The incidence of primary and secondary end points is presented in Figure 3 and Table 3. The absolute frequency and incidence of POAF after aortic root, ascending aorta, and aortic arch surgery in the PS-matched cohort was 64 patients (28.8%) overall, with that of the landiolol group being significantly lower than that of the reference group (21 [18.9%] vs 43 [38.7%]; P = .002) (Figure 3 and Table 3). Landiolol use was associated with a reduction in POAF incidence (odds ratio [OR], 0.39; 95% CI, 0.21-0.72; P = .003 by PS-matched analysis) (Table 4). A similar result was obtained by IPTW (OR, 0.39; 95% CI, 0.22-0.70; P = .002). Subgroup analysis suggested that the combination of landiolol with a postoperative beta-blocker provided an additional benefit (P value for interaction = .001) (Figure 3 and Table 4). Regarding the duration of POAF and cardioversion rate, there were no statistical differences between groups (Table 3). One patient in the landiolol group (n = 201) developed POAF after the completion of preventive landiolol administration, and landiolol was restarted for POAF cessation and heart rate control. In contrast, 20 patients in the reference group (n = 157) underwent pharmacologic cardioversion or heart rate control using landiolol for managing POAF; however, these patients were also treated as the reference group according to the definition of the

---

**TABLE 4. Association between landiolol treatment and incidence of postoperative atrial fibrillation in the propensity score (PS)-matched cohort and in subgroups**

| Variable                                | Odds ratio (95% CI) | P value |
|-----------------------------------------|---------------------|---------|
| PS-matched cohort (n = 222)             | 0.39 (0.21-0.72)    | .003    |
| Subgroup analysis                       |                     |         |
| Landiolol plus                           | 0.26 (0.10-0.63)    | .004    |
| postoperative beta-blocker (n = 54)     |                     |         |
| Landiolol alone (n = 57)                | 0.45 (0.20-0.98)    | .049    |
| Postoperative beta-blocker alone (n = 48)| 0.91 (0.42-1.97)   | .815    |
| Neither agent (n = 63)                  | 1.0*                |         |

*Reference category.

---

**FIGURE 2.** Histogram of propensity scores in landiolol (A) and reference (B) group.
landiolol group as patients who received landiolol at the operation room or within 3 hours after ICU admission (Figure 1).

Regarding the secondary end points in the PS-matched cohort, there were no significant differences in the 30-day mortality between the landiolol and reference groups (0 [0.0%] vs 3 [2.7%]; \( P = .247 \)), 30-day symptomatic cerebral infarction (9 [8.1%] vs 11 [9.9%]; \( P = .655 \)), 30-day readmission for arrhythmia after discharge (no events in both groups), length of hospital stay (31 days [IQR, 26-43 days] vs 32 days [IQR, 24-43 days]; \( P = .620 \)), length of ICU stay (5 days [IQR, 4-7 days] vs 5 days [IQR, 4-7 days]; \( P = .646 \)), length of mechanical ventilation (15.6 hours [IQR, 10.0-30.0 hours] vs 14.9 hours [IQR, 11.3-21.3 hours]; \( P = .943 \)), need for pacemaker support (46 patients [41.4%] vs 51 patients [45.9%]; \( P = .492 \)), mean blood pressure (78 mm Hg [IQR, 74-83 mm Hg] vs 79 mm Hg [IQR, 74-83 mm Hg]; \( P = .449 \)) and mean heart rate (80 bpm [IQR, 74-83 bpm] vs 79 bpm [74-83 bpm]; \( P = .797 \)). In addition, there was no early death within 72 hours after surgery.

FIGURE 3. The incidence of postoperative atrial fibrillation (POAF) in the propensity-matched cohort (A) and each subgroup (B). Both (n = 54) included patients who received both landiolol and postoperative oral or transdermal beta-blockers. Landiolol (n = 57) included patients who received landiolol administration. Beta (n = 48) included patients who received postoperative oral or transdermal beta-blockers. Neither (n = 63) included patients who did not receive neither landiolol nor postoperative beta-blockers.
during the study period, and we did not need to consider this competing risk in the analysis.

**DISCUSSION**

Our main finding was that intravenous landiolol is associated with a lower incidence of POAF after aortic root, ascending aorta, and aortic arch surgery in a PS-matched cohort (Figure 4 and Video 1). The OR of developing POAF was 0.39 (95% CI, 0.21-0.72; \( P = .003 \)) with landiolol use. The robustness of the result was confirmed by IPTW analysis. There were no significant differences in secondary end points such as the 30-day mortality and symptomatic cerebral infarction. Because little is known regarding the association between landiolol and POAF incidence after aortic root, ascending aorta, and aortic arch surgery, our results bridge this gap of evidence in the literature. Our findings could contribute to the appropriate management of POAF after aortic root, ascending aorta, and aortic arch surgery.

**Preventive Effects on POAF**

In the present study, we demonstrated that intravenous landiolol was associated with a lower incidence of POAF, with an OR of 0.39. Aortic root, ascending aorta, and aortic arch surgery is among the most invasive isolated operations in the field of cardiovascular surgery, with historically the highest incidence of POAF (49%-52%) when compared with that of CABG and valve surgery.\(^4\,^5\) POAF is caused by multiple factors such as inflammation, oxidative stress, operative trauma, changes in atrial pressure, sympathetic stimulation, and hypothermia.\(^29\,^30\) Among the above therapeutic targets, inhibition of sympathetic stimulation using beta-blockers is one of the most widely adopted option for the management of POAF due to the efficacy and safety.

---

### FIGURE 4.

Our main finding was that intravenous landiolol administration is associated with a lower incidence of postoperative atrial fibrillation (POAF) after aortic root, ascending aorta, and aortic arch surgery in a propensity score (PS)-matched cohort.

---

### VIDEO 1.

We retrospectively divided 358 eligible patients into 2 groups and estimated the therapeutic influence of landiolol on the prevention of postoperative atrial fibrillation (POAF) by propensity matched analysis. The landiolol was associated with a lower incidence of POAF than that of reference group. This study showed that landiolol can be a therapeutic option for the prevention of POAF after aortic root, ascending aorta, and aortic arch surgery. Video available at: [https://www.jtcvs.org/article/S2666-2736(22)00281-9/fulltext](https://www.jtcvs.org/article/S2666-2736(22)00281-9/fulltext).
of these agents. The high $\beta_1$-to-$\beta_2$ selectivity ratio of landiolol hydrochloride (250:1) might explain its favorable influence. Several systematic reviews and meta-analyses have suggested that landiolol is effective for POAF prevention after CABG and valve surgery, with most conclusions obtained from patients subjected to CABG. Our data on aortic root, ascending aorta, and aortic arch surgery provide complementary information in this field. The >50% reduction in the relative risk for POAF would also be useful information for clinicians.

Utility of Landiolol
There were no significant differences in secondary end points such as mean blood pressure, heart rate, and the need for pacemaker support between the landiolol group and the reference group. The European Association for Cardio-Thoracic Surgery guidelines on perioperative medication in adult cardiac surgery list perioperative oral beta-blockers as a class 2a recommendation for the prevention of POAF. It is also common consensus that oral beta-blockers should be re instituted at the earliest after surgery to reduce the incidence of POAF, as indicated in the American College of Cardiology Foundation and American Heart Association guidelines. From these viewpoints, among the advantages of landiolol is its capability to be administered intravenously, rendering it easy to achieve target drug concentrations without any time delay. Moreover, it is known that gastrointestinal edema associated with CPB can interfere with effective absorption of oral beta-blockers and delay the achievement of target drug concentrations. The short half-life of landiolol with minimal negative inotropic effects can also be an advantage because these properties lead to good controllability of the hemodynamic status in postoperative clinical settings.

Clinical Implications
In the present study, we demonstrated that landiolol was associated with a lower incidence of POAF with no statistical differences in adverse clinical events. Although observational data were utilized in our study, attempts have been made to eliminate the influence of confounding factors by estimating the therapeutic effects of landiolol in preventing POAF using PS-matched analyses. The robustness of the result was confirmed by IPTW. As a result, the relative risk was found to be less than half. Thus, the clinical implication of the present study is quite simple. Physicians or surgeons should consider landiolol as a therapeutic option for the prevention of POAF after aortic root, ascending aorta, and aortic arch surgery. Because few reports have investigated the efficacy and safety of landiolol for the prevention of POAF after such surgery, we hope that the present study contributes to efforts in minimizing POAF and achieving better prognosis in clinical settings.

Study Limitations
Several limitations of the present study should be considered when interpreting the results. First, because this was a single-center retrospective observational study, the therapeutic effects of landiolol for the prevention of POAF could not be determined despite the attempts made to eliminate the influence of confounding factors by performing PS-matched or IPTW analyses. Especially, it is unclear how our hypothermia protocol influences the generalizability of the study results given the association between hypothermia and arrhythmic events such as POAF. Second, several patient background characteristics could not be well balanced; thus, we evaluated the robustness of the results using IPTW. Third, the prescription rate of postoperative oral or transdermal beta-blockers was quite low partly because their use for the prevention of POAF was not covered by medical insurance in Japan during the study period. Fourth, the small sample sizes in the subgroup analysis may limit meaningful conclusions. Fifth, differences in hard end points such as the 30-day mortality and cerebral infarction were statistically underpowered because of the low incidence of these events and the small study population. The sample size was too small to address the more serious consequences of POAF in this study and we need more investigations or meta-analysis. Hence, further evaluations by larger cohort studies or randomized trials are warranted.

CONCLUSIONS
Intravenous landiolol administration was associated with a lower incidence of POAF in a PS-matched cohort after aortic root, ascending aorta, and aortic arch surgery.

Conflict of Interest Statement
The authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

The authors thank the Japan Society of Clinical Research for their dedicated support.

References
1. Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017;52:665-72.
2. Nakanishi K, Takeda S, Kim C, Kohda S, Sakamoto A. Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. J Cardiothorac Surg. 2013;8:19.
3. Khan J, Khan N, Loisa E, Sutinen J, Laurikka J. Increasing occurrence of postoperative atrial fibrillation in contemporary cardiac surgery. J Cardiothorac Vasc Anesth. 2016;30:1302-7.
4. Deschka H, Erler S, Machner M, El-Ayoubi L, Alken A, Wimmer-Greinecker G. Surgery of the ascending aorta, root remodelling and aortic arch surgery with circulatory arrest through partial upper sternotomy: results of 50 consecutive cases. Eur J Cardiothorac Surg. 2013;43:580-4.
5. Matsuura K, Ogino H, Matsuura H, Minatoya K, Sasaki H, Kada A, et al. Prediction and incidence of atrial fibrillation after aortic arch repair. *Ann Thorac Surg*. 2006;81:514-8.

6. Attaran S, Shaw M, Bond L, Pullan MD, Fabri BM. Atrial fibrillation postcardiac surgery: a common but a morbid complication. *Interact Cardiovasc Thorac Surg*. 2011;12:772-7.

7. Arsenault KA, Yusuf MA, Crystal E, Healey JS, Morillo CA, Nair GM, et al. Interventions for preventing postoperative atrial fibrillation in patients undergoing heart surgery. *Cochrane Database Syst Rev*. 2013;2013:CD003611.

8. Balik M, Sander M, Trimell H, Heinz G. Landiolol for managing post-operative atrial fibrillation. *Eur Heart J Suppl*. 2018;20:A10-4.

9. Kugo Y, Nishi H, Sekiya N, Yamada Y, Takahashi M, Takehashi K. Postoperative atrial fibrillation. *Kyobu Geka*. 2018;71:83-7.

10. Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, et al. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. *Heart Vessels*. 2013;28:490-6.

11. Maiaiwara H, Sakurai M, Namai A, Kawamura T. Effect of low-dose landiolol, an ultra-short-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery. *Gen Thorac Cardiovasc Surg*. 2009;57:132-7.

12. Ito N, Tashiro T, Morishige N, Nishimi M, Hayashida Y, Minematsu N, et al. Safety and efficacy of an ultra-short-acting beta-blocker on left ventricular dysfunc tion. *Heart Surg Forum*. 2012;15:E189-94.

13. Tanaka K. Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting. *Kyobu Geka*. 2010;63:764-8.

14. Nakaoka E, Arai H, Tamura K, Makita S, Miyagi N. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. *J Cardiovasc Surg (Torino)*. 2012:53:369-74.

15. Ogawa S, Okawa Y, Goto Y, Aoki M, Baba H. Perioperative use of a beta blocker in coronary artery bypass grafting. *Asian Cardiovasc Thorac Ann*. 2013;21:170-5.

16. Nakao M, Bessho R, Omi M, Shimizu K, Terajima K, Takeoka S. Effect of perioperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. *J Cardiovasc Surg (Torino)*. 2012:53:369-74.

17. Ogawa S, Okawa Y, Goto Y, Aoki M, Baba H. Perioperative use of a beta blocker in coronary artery bypass grafting. *Asian Cardiovasc Thorac Ann*. 2013;21:265-9.

18. Sezai A, Minami K, Nakai T, Hata M, Yoshitake I, Wakai S, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. *J Thorac Cardiovasc Surg*. 2011;141:1478-87.

19. Sezai A, Nakai T, Hata M, Yoshitake I, Shinomi M, Kumimoto S, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. *J Thorac Cardiovasc Surg*. 2012;144:1241-8.

20. Sakaguchi M, Sasaki Y, Hirai H, Hosono M, Nakahira A, Sato H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. *Int Heart J*. 2012:53:559-63.

21. Sezai A, Osaka S, Tashiro T, Yoshitake I, Arimoto M, Hata H, et al. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction (PLATON trial). *J Thorac Cardiovasc Surg*. 2015;150:975-84.

22. Sakamoto A, Kitakaze M, Takamoto S, Namiki A, Kasanuki H, Hosoda S, et al. Landiolol, an ultra-short-acting beta-blocker, more effectively reduces atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). *Circ J*. 2012;76:1097-101.

23. Hara M, Sakata Y, Nakatani D, Suna S, Usami M, Matsumoto S, et al. Comparison of 5-year survival after acute myocardial infarction using angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. *Am J Cardiol*. 2014;114:1-8.

24. Uchiyama Y, Unoki K, Sakoda N, Saiti M, Hisamochi K, Yoshida H, et al. Innominate artery cannulation for arterial perfusion during aortic arch surgery. *J Card Surg*. 2017;32:110-3.

25. Filardo G, Damiano RJ Jr, Ailawadi G, Thourani VH, Pollock BD, Sass DM, et al. Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery. *Heart*. 2018;104:985-92.

26. Li L, Ai Q, Lin L, Ge P, Yang C, Zhang L. Efficacy and safety of landiolol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. *Int J Clin Exp Med*. 2015;8:10265-73.

27. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. *Stat Med*. 2013;32:2837-49.

28. Zakkar M, Asciene R, James AF, Angelini GD, Suleiman MS. Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery. *Pharmacol Ther*. 2015;154:15-20.

29. Hicks E, Micord C, Blounttj G. Electrocardiographic changes during hypother mia and circulatory occlusion. *Circulation*. 1956;13:21-8.

30. Sousa-Uva M, Head SJ, Milovic M, Collet JP, Landoni G, Castella M, et al. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. *Eur J Cardiothorac Surg*. 2018;53:5-33.

31. Gillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery executive summary. A report of the American College of CardiologyFoundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2011;124:2610-42.

32. Kim SH, Jang MJ, Hwang HY. Perioperative beta-blocker for atrial fibrillation after cardiac surgery: a meta-analysis. *Thorac Cardiovasc Surg*. 2021;69:133-40.

33. Tamura T, Yatabe T, Yokoyama M. Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: a systematic review and meta-analysis. *J Clin Anesth*. 2017;42:1-6.

34. Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trial. *Adv Ther*. 2014;31:440-50.

**Key Words:** atrial fibrillation, landiolol hydrochloride, beta-blocker, aortic surgery